Your browser doesn't support javascript.
loading
Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Bruzzi, M; Auclin, E; Lo Dico, R; Voron, T; Karoui, M; Espin, E; Cianchi, F; Weitz, J; Buggenhout, A; Malafosse, R; Denimal, F; Le Malicot, K; Vernerey, D; Douard, R; Emile, J F; Lepage, C; Laurent-Puig, P; Taieb, J.
Afiliación
  • Bruzzi M; Department of General and Digestive Surgery, Georges Pompidou European Hospital, AP-HP, Paris, France. matthieu.bruzzi@aphp.fr.
  • Auclin E; Department of Digestive Oncology, Georges Pompidou European Hospital, AP-HP, Paris, France.
  • Lo Dico R; Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besançon, Besançon, France.
  • Voron T; Department of Digestive and Oncological Surgery, Lariboisière Hospital, AP-HP, Paris, France.
  • Karoui M; Department of Digestive and General Surgery, Saint Antoine Hospital, AP-HP, Sorbonne Université, Paris, France.
  • Espin E; Department of Digestive and Hepato-Pancreato-Biliary Surgery, Pitié-Salpêtrière University Hospital, AP-HP, Paris VI University Institute of Cancerology, Paris, France.
  • Cianchi F; Department of General Surgery, Hospital Valle de Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Weitz J; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Buggenhout A; Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus of the Technical University Dresden, Dresden, Germany.
  • Malafosse R; Department of Surgical Gastroenterology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Denimal F; Department of Digestive Surgery, Ambroise-Paré Hospital, AP-HP, Boulogne, France.
  • Le Malicot K; Department of Digestive Surgery, Centre Hospitalier Départemental Vendée, La Roche Sur Yon, France.
  • Vernerey D; Statistical Department, Fédération Francophone de Cancérologie Digestive, EPICAD, INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, Dijon, France.
  • Douard R; Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besançon, Besançon, France.
  • Emile JF; Department of General and Digestive Surgery, Georges Pompidou European Hospital, AP-HP, Paris, France.
  • Lepage C; Pathology Department, Ambroise-Paré Hospital, AP-HP, Boulogne, France.
  • Laurent-Puig P; Hepato-Gastroenterology Department, Dijon University Hospital and EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.
  • Taieb J; Department of Biology, European Georges Pompidou Hospital, AP-HP, INSERM-UMR-S1147, Paris, France.
Ann Surg Oncol ; 26(11): 3561-3567, 2019 Oct.
Article en En | MEDLINE | ID: mdl-31209667
BACKGROUND: Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain unclear. The objective of the study was to assess recurrence patterns according to microsatellite instability (MSI), RAS and BRAFV600E status in stage III CC patients. METHODS: All stage III CC patients from the PETACC-8 randomized trial tested for MSI, RAS and BRAFV600E status were included. The site and characteristics of recurrence were analyzed according to molecular status. Survival after recurrence (SAR) was analyzed. RESULTS: A total of 1650 patients were included. Recurrence occurred in 434 patients (26.3%). Microsatellite stable (MSS) patients had a significantly higher recurrence rate (27.2% vs. 18.7%, P = 0.02) with a trend to more pulmonary recurrence (28.8% vs. 12.9%, P = 0.06) when compared to MSI patients. MSI patients experienced more regional lymph nodes compared to MSS (12.9% vs. 4%, P = 0.046). In the MSS population, the recurrence rate was significantly higher in RAS (32.2%) or BRAF (32.3%) patients when compared to double wild-type patients (19.9%) (p < 0.001); no preferential site of recurrence was observed according to RAS and BRAFV600E mutations. Finally, decreased SAR was observed in the case of peritoneal recurrence or more than two recurrence sites. CONCLUSIONS: Microsatellite, RAS and BRAFV600E status influences recurrence rates in stage III CC patients. However, only microsatellite status seems to be associated with specific recurrence patterns. More than two recurrence sites and recurrence in the peritoneum were associated with poorer SAR.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias del Colon / Proteínas ras / Proteínas Proto-Oncogénicas B-raf / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias del Colon / Proteínas ras / Proteínas Proto-Oncogénicas B-raf / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos